| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Inactivated poliovirus vaccine: past and present experience.
|
Vaccine
|
1996
|
1.22
|
|
2
|
Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age.
|
Vaccine
|
1998
|
1.14
|
|
3
|
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants.
|
J Pediatr
|
1997
|
1.10
|
|
4
|
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age.
|
Pediatr Infect Dis J
|
1994
|
1.07
|
|
5
|
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
|
Vaccine
|
2000
|
1.05
|
|
6
|
Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children.
|
CMAJ
|
1991
|
1.04
|
|
7
|
Measles vaccination of infants in a well-vaccinated population.
|
Pediatr Infect Dis J
|
1995
|
0.97
|
|
8
|
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
|
Vaccine
|
2012
|
0.93
|
|
9
|
An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
|
Pediatrics
|
1999
|
0.90
|
|
10
|
Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data.
|
Vaccine
|
2008
|
0.86
|
|
11
|
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
|
Pediatr Infect Dis J
|
2000
|
0.85
|
|
12
|
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?
|
CMAJ
|
1993
|
0.83
|
|
13
|
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children.
|
Vaccine
|
1995
|
0.83
|
|
14
|
Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants.
|
Vaccine
|
1999
|
0.81
|
|
15
|
Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection.
|
Vaccine
|
1992
|
0.81
|
|
16
|
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria.
|
Clin Exp Immunol
|
1991
|
0.81
|
|
17
|
Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia.
|
Can Dis Wkly Rep
|
1989
|
0.80
|
|
18
|
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
|
Pediatr Infect Dis J
|
1999
|
0.80
|
|
19
|
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life.
|
Vaccine
|
1996
|
0.79
|
|
20
|
[Quality evaluation of primary health care in an urban area of southern Brazil].
|
Rev Saude Publica
|
1994
|
0.78
|
|
21
|
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
|
Scand J Infect Dis
|
1995
|
0.77
|
|
22
|
Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
|
Arch Pediatr Adolesc Med
|
1994
|
0.77
|
|
23
|
Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination.
|
Dev Biol Stand
|
1998
|
0.77
|
|
24
|
Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age.
|
Pediatr Infect Dis J
|
1995
|
0.76
|
|
25
|
Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines.
|
J Pediatr
|
1999
|
0.76
|
|
26
|
Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities.
|
Arch Pediatr Adolesc Med
|
1994
|
0.76
|
|
27
|
Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine.
|
Vaccine
|
1997
|
0.76
|
|
28
|
Controlled study of a new five-component acellular pertussis vaccine in adults and young children.
|
J Infect Dis
|
1992
|
0.76
|
|
29
|
[Research on human vaccine and its trends of application].
|
Zhonghua Yi Xue Za Zhi
|
1998
|
0.75
|
|
30
|
Stability of BCG vaccine (intravesical) Theracys/BCG therapeutic ImmuCyst and its importance in clinical efficacy.
|
Dev Biol Stand
|
1992
|
0.75
|
|
31
|
Standardization of BCG multiple puncture 40 mg and BCG live (intravesical) Theracys/BCG therapeutic Immucyst.
|
Dev Biol Stand
|
1992
|
0.75
|
|
32
|
Interesting case: an unusual case of oral ulceration.
|
Br J Oral Maxillofac Surg
|
2005
|
0.75
|
|
33
|
Reversible zidovudine-induced pure red cell aplasia.
|
AIDS
|
1999
|
0.75
|
|
34
|
Smokeless tobacco: a northern perspective.
|
Can Nurse
|
1987
|
0.75
|
|
35
|
The launch of an infant Haemophilus influenzae type B immunization programme in Iceland.
|
Arctic Med Res
|
1991
|
0.75
|